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Objective: To evaluate the association of patient-reported severity of painful diabetic peripheral 
neuropathy (pDPN) with other outcomes in a European population of patients using the Adelphi 
Disease Specific Programme for pDPN (DSP III, 2008).
Methods: The severity of patients’ pDPN (mild, moderate, or severe) was rated   independently 
by both patients and physicians. Relationships were evaluated between patient-reported 
pDPN severity and other patient-reported outcomes including pain, sleep, function, and work 
  productivity. Physicians rated the severity of patients’ pDPN (1 = mild, 2 = moderate, 3 = severe) 
and sleep interference.
Results: Patient-reported data were available from 634 individuals (56.2% male, mean age 
63 years) from France, Germany, Italy, and the UK, of whom only 22.2% reported that they 
were currently employed. pDPN severity was rated as mild, moderate, and severe by 22.2%, 
60.9%, and 16.9% of the patients, respectively. There was a significant association between 
patient-rated and physician-rated pDPN severity (P , 0.0001), although there were discrepancies 
in agreement (kappa = 0.37, 95% confidence interval [CI] 0.31, 0.43; weighted kappa = 0.43, 
95% CI 0.37, 0.48) among physician and patient ratings in a substantial proportion of patients 
across severity categories. Higher pDPN severity was associated with greater interference of 
daily function including sleep (P , 0.0001 for all pairwise comparisons). Among employed 
patients, percent of pDPN-related impairment while at work (presenteeism) and overall work 
impairment increased with greater pDPN severity, resulting in indirect costs that increased 
significantly with pDPN severity; $8266, $15,449, and $24,300 for mild, moderate, and severe 
pDPN, respectively (overall P , 0.001).
Conclusion: Severity of patient-rated pDPN was significantly associated with outcomes, 
including function and productivity; poorer function and lower productivity were reported at 
higher pDPN severity levels. Moreover, physicians rated pDPN severity different from patients 
in a substantial proportion of patients.
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Introduction
The diabetic neuropathies comprise a family of nerve disorders that are common 
complications of diabetes and can result in chronic, persistent, neuropathic pain.1 
These neuropathies occur with a similar frequency among patients with type 1 and 
type 2 diabetes, 59% and 66%, respectively.2 Painful diabetic peripheral neuropathy 
(pDPN) is a variant of distal symmetrical sensorimotor polyneuropathy, the most 
common form of diabetic neuropathy.3 Although best estimates suggest that only 
15% of patients with diabetes have pDPN,1 the symptoms of chronic pain and reduced Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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function have a profound impact on patients and result in a 
substantial burden relative to both the general population and 
to diabetic patients without pDPN.1,4–14
Although updated guidelines for the treatment of neuro-
pathic pain have recently been published,15–18 treatment of 
pDPN remains challenging, especially given the   presence 
of comorbidities, contraindications, and use of other 
medications with potential interactions.19
Understanding pDPN severity and its impact on the 
patient and societal burdens can help inform development 
and application of appropriate management strategies. In 
particular, given the subjective and multidimensional nature 
of pain, such an understanding is especially important when 
considered from the patients’ perspective.
The identification of established cut points for character-
izing mild, moderate, and severe pain associated with pDPN20 
has enhanced the ability to evaluate the relationship between 
pain and other outcomes. Several studies have evaluated these 
relationships, and reported that the magnitude of the effects 
of pDPN pain on outcomes of function, sleep, quality of life, 
depression, and anxiety was higher at greater levels of pain 
severity.9–11,21 However, a broader approach that considers 
severity of pDPN as a condition, not just pain severity, may 
provide a more clinically relevant patient perspective of 
  severity and impact. Such an approach has been used in other 
painful conditions including osteoarthritis and chronic low 
back pain.22–24 Additionally, only limited quantitative data 
exist on the impact of pDPN on productivity. One study 
reported that lost productive time among diabetic patients 
with neuropathic symptoms was higher than among diabetic 
patients without such symptoms, and 18% higher than non-
diabetic controls.6 A more recent study demonstrated that 
work productivity was significantly lower with increasing 
pain severity, and that costs related to lost productivity 
increased with greater levels of pain.21 Therefore, the   purpose 
of this study was to explore the relationship between patient-
reported severity of pDPN and health indicators, as well 
as to quantitatively assess the impact of pDPN severity on 
productivity.
Methods
Data source
The Adelphi Disease Specific Program (DSP) represents an 
aggregated database from a cross sectional study of consulting 
patients, which includes patient-level and physician-reported 
data on specific chronic diseases.25 Data are collected in 
clinical practice settings by physicians who provide relevant 
information on consecutive patients who consulted for the 
disease of interest. Patients are invited to participate by 
completing questionnaires on symptoms, expectations, and 
QOL. The current analysis, which is based on the Neuropathic 
Pain III DSP conducted in 2008 in Europe among patients 
with a variety of neuropathic pain conditions, focuses on 
the subset of patients who were identified with a confirmed 
diagnosis of pDPN. Data are included from subjects from 
France, Germany, Italy, and the United Kingdom. Physician 
practices captured by this DSP were those in primary care as 
well as the following specialties: neurology, anesthesiology, 
diabetology, orthopedic surgery, and rheumatology.
Outcomes
In contrast to other studies that used a single question asking 
patients to rate their disease severity as mild, moderate, or 
severe, this analysis did not rely on a direct question, but 
rather determined pDPN severity based on two questions. 
The first question asked patients to identify and rate 
(mild, moderate, and severe) their most common types of 
neuropathic pain sensations (hot/burning, tingling, aching, 
shooting, stabbing, sharp, pins and needles, numbness, tight, 
electrical, dull, other). The second question asked patients to 
identify painful areas of the body and rate the pain of their 
most commonly painful body part. While patients could 
identify multiple body locations of pain, only a single body 
part was considered for pain severity. When considering the 
overall rating of pDPN severity, the default was severity of 
neuropathic pain sensations if there was discordance between 
the two ratings.
Patient-reported pain severity and interference with 
function was captured using the Brief Pain Inventory-Short 
Form (BPI-SF).26 Four questions focus on pain severity using 
a 0–10 numerical rating scale (NRS; 0 = no pain, 10 = pain as 
bad as you can imagine): worst, least, average, and current pain 
with a 24-hour recall period for the first three items. Patients 
were stratified as having mild, moderate, or severe pain using 
the cut points of 0–3, 4–6, and 7–10, respectively, which were 
previously identified in patients with pDPN.20 Seven items 
on the BPI-SF measure pain interference with daily function 
(0 = does not interfere, 10 = completely interferes), including 
sleep. Pain severity and pain interference with daily function 
were assessed by averaging the four pain severity items and 
the seven pain interference items, respectively. Additionally, 
evaluation of pDPN severity on sleep was specifically 
evaluated using the appropriate item from the BPI-SF for 
patient-reported sleep, and physician’s assessment based on 
the question “In your opinion to what extent does the patient’s 
neuropathic pain interfere with sleep?”Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4
Table 1 Demographic characteristics of the study population   
(n = 634)
Characteristic Value
gender, n (%)
  Male 355 (56.2)
  Female 277 (43.8)
Age, years
  Mean ± standard deviation 63.0 ± 11.4
  range 23–89
country, n (%)
  France 162 (25.6)
  germany 230 (36.3)
  italy 158 (24.9)
  United Kingdom 84 (13.3)
ethnicity, n (%)
  White 595 (94.2)
  non-white 37 (5.9)
employment status, n (%)
  Full-time 128 (20.5)
  Part-time 11 (1.8)
  homemaker 59 (9.4)
  retired 365 (58.3)
  Unemployed 63 (10.1)
Body mass index
  Mean ± standard deviation, kg/m2 27.2 ± 4.8
 $ 30, n (%) 318 (50.4)
Time since diagnosis, years
  Mean standard deviation 1.8 ± 2.1
  range 0–17.3
common comorbidities ($5% of patients), n (%)
  hypertension 369 (58.2)
  hypercholesterolemia 246 (38.8)
  cardiovascular conditions 110 (17.4)
  Sleep disorders 107 (16.9)
  Osteoarthritis 95 (15.0)
  clinical depression 86 (13.6)
  Feelings of depression 66 (10.4)
  clinical anxiety 48 (7.8)
  Feelings of anxiety 44 (6.9)
Note: numbers may not add up to 634 because of missing data.
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Work productivity was captured using the Work 
  Productivity and Activity Impairment scale (WPAI).27 
The WPAI consists of six questions with the first question 
on employment status. The remaining five questions, 
referenced to the past 7 days, relate to hours missed because 
of neuropathic pain; hours missed because of other reasons; 
hours actually worked; degree neuropathic pain affected 
productivity while working (rating scale from 0 = no effect 
to 10 = completely prevented from working); and degree 
neuropathic pain affected regular activities (rating scale 
0 = no effect to 10 = completely prevented daily activities). 
By summing and dividing these responses accordingly, the 
percent work time missed due to pDPN (absenteeism) can 
be calculated, as well as the percent impairment while on 
the job due to this condition (presenteeism), percent overall 
work impairment and the percent activity impairment due 
to their condition. Costs, in euros and dollars, due to lost 
productivity were calculated using the method of Lofland 
et al,28 based on average annual wages for 2008 in the EU 
estimated from published sources (http://data.worldbank.
org/indicator/NY.GNP.PCAP.CD) and the average dollar 
to euro rate for 2008 (http://www.irs.gov/businesses/small/
international/article/0,,id=206089,00.html).
Physicians also provided a rating of patient’s pDPN 
severity in response to the question “Which one of these 
best describes your view of the severity of the patient’s 
neuropathic pain condition?” with potential responses 
of 1 = mild, 2 = moderate, 3 = severe, 4 = very severe. 
Physician ratings were obtained independently of the 
patient’s ratings.
Statistical analysis
The relationship between severity of neuropathic pain 
sensations and severity of the most commonly painful body 
part was specifically evaluated using the nonparametric 
Spearman rank correlation. Overall patient-reported pDPN 
severity, stratified by mild, moderate, and severe, was further 
evaluated for relationships with other patient-reported 
outcomes. Pre-specified analyses were performed using 
STATA 10.1 data analysis and statistical software (StataCorp 
LP, College Station, Texas, USA). Analysis of variance 
(ANOVA) and t-tests were used for interval and count data; 
chi-squared tests, or Fisher exact test for binary variables 
were used for categorical data; and Kruskal–Wallis tests or 
Mann–Whitney tests were conducted on pairwise severity 
comparisons for ordinal data. All multiple comparisons were 
Bonferroni corrected. Evidence for statistical significance 
was based on a P value ,0.05.
Results
Patient-reported data were available from 634 individuals 
identified as having a confirmed diagnosis of pDPN, 
162 (25.6%) from France, 230 (36.3%) from Germany, 
158 (24.9%) from Italy, and 84 (13.2%) from the UK. 
Diagnosis was confirmed by a diabetologist or neurolo-
gist in 30.1% and 28.3% of cases, respectively, followed 
by primary care physicians (24.8%); the remaining 16.8% 
of cases were confirmed by other physician specialties 
or a   combination of physician types. The demographic 
characteristics of this population, shown in Table 1 indicate 
that they were   predominantly male (56.2%), with a mean age 
of 63.0 ± 11.4 years, and a mean time since pDPN diagnosis 
of 1.8 ± 2.1 years; approximately half the population (50.4%) Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4
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Figure 1 Proportion of patients rating their painful diabetic peripheral neuropathy 
as mild, moderate, and severe.
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noticeable with   physicians underestimating 46.7% of the 
patients who reported severe pDPN.
Pain severity and pain interference with daily function 
demonstrated significant increases with increasing pDPN 
severity (Figure 2). Impact on sleep also significantly 
increased with increasing pDPN severity (P , 0.0001) 
(Figure 3), and all pairwise severity comparisons for both 
patient and physician assessments of sleep were significant 
(P , 0.0001).
Among the employed individuals for whom WPAI data 
were available, there was a significant association between 
pDPN severity and work productivity (P , 0.05) (Figure 4). 
In particular, the percent overall activity impairment was 
significantly higher with increasing pDPN severity levels 
(P , 0.0001 for all pairwise comparisons). Employed 
individuals reported greater impairment while working and 
greater overall working impairment at increasing pDPN 
severity levels, which were significant for mild versus severe 
(P , 0.001) and moderate versus severe (P , 0.05). Estimated 
annual costs related to lost work productivity among employed 
individuals with pDPN increased significantly with pDPN 
severity (Figure 5); €5,646 ($8,266), €10,552 ($15,449), 
and €16,597 ($24,300) for mild, moderate, and severe 
pDPN, respectively (overall P = 0.0002 and P , 0.05 for all 
pairwise comparisons). These costs appeared to be primarily 
driven by presenteeism, ie, impairment while working. Mean 
total costs of lost productivity across severity categories 
were €15,446 ± 12,272 ($10,549 ± 8,383) and were similar 
among the countries; €8,185 ± 6,376 ($11,984 ± 9,335) 
for Italy, €10,789 ± 8,823 ($15,797 ± 12,918) for France, 
€10,828 ± 9,042 ($15,853 ± 13,238) for Germany, and 
€12,438 ± 8,573 ($18,211 ± 12,552) for the UK.
Discussion
An understanding of the relationship between pDPN severity 
and other outcomes affected by this condition can help 
characterize the disease burden and enhance development 
and application of appropriate management strategies. The 
results presented here, which represent a subset of patients 
with pDPN from a survey of patients with neuropathic pain 
conditions, provide a European perspective and expand on 
previous studies that showed a significantly greater patient 
burden associated with pDPN at higher pain severity levels.9,11 
In contrast to those studies, which specifically evaluated pain 
severity, the current analysis included more than just pain 
to define pDPN as a condition, with particular emphasis on 
neuropathic pain-related symptoms. Importantly, the strong 
correlation between severity of sensations and body part 
had a body mass index $30, indicating obesity. Only 22.4% 
of subjects reported that they were currently employed; 
58.3% were retired, 10.1% were unemployed, and 9.4% 
stated that they were homemakers.
Pain was reported in multiple body sites in 38.5% of 
patients. Overall, patients identified the lower extremities 
(leg or foot) as their most frequent location of neuropathic 
pain (91.4%). Among patients who reported a single body 
location for pain (n = 375), 92.8% reported neuropathic pain 
in the leg or foot.
The proportion of patients who rated their pDPN condi-
tion as mild, moderate, and severe was 22.2%, 60.9%, and 
16.9%, respectively, and these proportions were similar 
across the countries (Figure 1). The two items used to assess 
condition severity were strongly correlated (Spearman 
r = 0.7165), with substantial agreement between ratings also 
indicated by the kappa coefficient (0.6087, 95% CI 0.5504, 
0.6670) and the weighted kappa (0.6516, 95% CI 0.5940, 
0.7091). There was no association of pDPN severity with 
demographic variables including age, gender, BMI, or overall 
employment status. Similarly, there was no association of 
pDPN severity with disease duration.
For physician-rated severity, since there were only 
8 patients who were rated as very severe, these patients 
were incorporated into the severe category. There was 
a clear and significant association observed between 
  patient-rated and physician-rated severity (P , 0.0001). 
However, when   analyzed using a 3-by-3 contingency table 
(Table 2),   ratings showed discrepancies in agreement 
(kappa = 0.37, 95% CI 0.31, 0.43; weighted kappa = 0.43, 
95% CI 0.37, 0.48).   Discordance between physician and 
patient ratings was   evident in a substantial proportion of 
patients across severity categories, and was especially Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4
Table 2 Physician-reported versus patient-reported severity of painful diabetic neuropathy as a condition (weighted kappa coefficient = 0.43; 
95% confidence interval 0.37, 0.48)
Patient-reported  
severity
Physician-reported severity, n Row total,  
n (%)
pDPN severity discordance,   
percent of patients Mild Moderate Severe*
Mild Frequency 80 52 6 138 (22.0) 42.0
Moderate Frequency 45 268 70 383 (61.2) 30.0
Severe Frequency 3 46 56 105 (16.8) 46.7
column total, n (%) 128 (20.5) 366 (58.5) 132 (21.1) 626 (100) 35.5
Note: *includes “very severe” (n = 8).
Abbreviation: pDPn, painful diabetic peripheral neuropathy.
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severity suggests that pain is not the sole component   driving 
the rating of pDPN severity. Additionally, these results 
show that pDPN severity correlated well with pain, sleep, 
interference with function, and work productivity.
Information on body regions affected by pDPN is 
lacking. One study, in a small number of patients, reported 
that neuropathic pain was always located in the feet,29 and 
evidence from other studies suggested that trigeminal and 
facial nerves may also be affected.30,31 While the lower 
extremities were the most commonly reported source of 
neuropathic pain in the current study, the anatomic location 
of neuropathic pain was not limited to this region of the body, 
and approximately half the patients reported neuropathic pain 
in other body parts, although quantitative sensory testing or 
neurophysiology to confirm the presence of neuropathic pain 
was not performed.
As pDPN severity increased, there was a corresponding 
increase in pain severity, pain interference with daily 
function, sleep, employment status, and work-related 
productivity impairment. Notably, with increasing pDPN 
severity, the change in pain severity was matched by the 
change in pain interference with function, suggesting close 
association between the patient’s perception of pDPN with 
that of both pain and functional ability. Pain interference at 
each pDPN severity level in the current study was within the 
range of values reported in previous studies for increasing 
pain severity levels.9,11
Especially notable was the significant association between 
pDPN severity and pain-related sleep interference, which 
was consistent with a previous study that showed greater 
sleep impairment at higher levels of pain severity.9 These 
associations are of clinical relevance given that pDPN not 
only results in substantial sleep impairment,32 but that sleep 
impairment has been shown to have a direct relationship with 
metabolic control, including increased risk for and severity 
of diabetes.33
Among patients who remained in the workforce, severity 
of pDPN was associated with lost productivity.   Interestingly, 
previous research has shown that among employed 
individuals with diabetes, those having neuropathic symp-
toms have significantly greater work loss than those without 
these symptoms.6
Our data suggest that among employed individuals, the 
magnitude of work loss increases with pDPN severity, and 
that most of this lost productivity is derived from impairment 
while at work, ie, presenteeism. Patients with moderate 
severity reported that approximately one-third of their work 
time (36.8%) was lost due to pDPN, and almost twice as 
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much lost work time (58.9%) was lost by patients with 
severe pDPN. These trends were similar to those observed 
in a US study that reported on pain severity and productivity 
in patients with pDPN.21 Additionally, these observations 
are consistent with the suggestion that presenteeism is the 
primary source of lost productive time, and is also likely to 
be the primary driver of indirect costs among workers with 
chronic pain conditions.34 In fact, indirect costs associated 
with lost productivity in the current study were significantly 
associated with pDPN severity, with indirect costs for a 
patient with severe pDPN (€16,597) approximately three 
times that of a patient with mild pDPN (€5,646).
Although there was some agreement between patient- and 
physician-rated pDPN severity (weighted kappa = 0.43), 
there was a substantial disparity between the physicians’ and 
patients’ ratings, with approximately one-third of patients’ 
ratings being over- or under-rated by physicians, including 
almost half of the patients who rated themselves as severe 
being rated by the physicians as mild or moderate. This result 
is consistent with the general finding in other conditions 
that clinicians and patients have different perspectives of 
severity, both underestimating and overestimating specific 
outcomes or overall disease severity.23,35–41 Such an effect, 
where physicians underestimate the severity of a patient’s 
condition, can conceivably result in a proportion of patients 
not receiving appropriate treatment. Conversely, if over-
estimated, the patients may receive medications that are 
not needed, unnecessarily increasing the risks that may be 
associated with specific medications.
Although the questions used to determine patient-rated 
severity were specific for neuropathic pain, it is possible 
that other factors contributed to these ratings and may 
in part account for the discordance between patient and 
physician ratings. In particular, the presence of pain-related 
comorbidities as well as neuropsychiatric conditions such as 
depression and anxiety, which were present in this population, 
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could potentially have an influence on patient perceptions 
of pDPN. Nevertheless, this disparity has several clinical 
implications, including the need for identifying factors 
contributing to severity that may be emphasized differentially 
by patients and physicians. This discrepancy strongly argues 
for the importance of the patient’s perspective, and suggests 
that physicians need to work closely with patients to gain a 
comprehensive assessment.
Interpretation and extrapolation of these results are subject 
to several limitations, including the fact that participation 
was based on agreement by physicians and patients. It is 
therefore possible that individuals who participated may 
have characteristics and perceptions different from those who 
refused to participate, thereby introducing selection bias and 
reducing generalizability.
While the population was drawn from a sample of patients 
with neuropathic pain, the demographics suggest that these 
patients are likely to be representative of patients with pDPN 
in the general diabetes population; older age,   predominantly 
male, and with a presence of risk factors for diabetes including 
obesity, hypertension, and hypercholesterolemia.
Recall bias when completing a questionnaire is another 
potential limitation, which was minimized for all of the 
  measures by using a maximum recall period of the past 7 days. 
Furthermore, because the data are only from 4 countries 
they may not necessarily be representative of the  European 
population, indicating the need for broader sampling.
That the type of employment was not captured in the 
questionnaire may also be considered a limitation, because 
it is likely to affect the magnitude of productivity loss among 
workers as well as the likelihood that employment status 
was compromised among those who stopped work because 
of their pDPN. Similarly, the analyses were not adjusted for 
the specific body parts where patients reported their most 
commonly occurring pain, because the body site is likely to 
affect daily function and productivity.
With regard to the diagnosis of pDPN for inclusion, this 
diagnosis is dependent on the diagnostic skill of the treating 
physician. Although diabetologists and neurologists were 
the diagnosing physicians in more than half the patients, 
the basis for the diagnosis (ie, quantitative sensory testing, 
neurography, etc) was not captured as part of the study, and 
therefore it is possible that misdiagnosis may have occurred 
in a small proportion of the sample population.
It should be noted that the cross-sectional nature of DSPs 
precludes causation. Since no cause and effect imputation 
can be made, the observed relationships should be considered 
associative rather than causal.
Conclusion
Severity of pDPN was significantly associated with pain, 
sleep, function, and lost productivity; poorer function 
and sleep, and lower productivity were reported at higher 
pDPN severity levels, with lower productivity also having 
a greater economic impact. In a proportion of patients there 
was substantial discordance between physician and patient 
ratings of pDPN severity. Further analyses of these observed 
relationships are warranted from the perspectives of both 
the patients and clinicians with the goal of refining targeted 
management strategies to meet the needs of the patients.
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